vivoPharm expands, TGR contracts
Wednesday, 06 February, 2008
Adelaide-based contract research organisation vivoPharm is to open a European subsidiary in Germany after receiving an injection of venture capital funds.
vivoPharm Europe will be based in Munich and headed by Dr Katja Wosikowski. It aims to develop new business and maintain relationships with existing customers in Austria, Germany, Switzerland, Spain and Norway.
vivoPharm was established in 2003 and offers integrated preclinical services to the biotechnology and pharmaceutical industries.
It received $1 million in venture capital from the South Australian Life Sciences Advancement Fund, managed by Terra Rossa Capital.
Another Adelaide biotech, TGR BioSciences, has appointed former PricewaterhouseCoopers (PwC) life sciences specialist Andrew Sneddon to its board.
TGR specialises in drug discovery for oral and gastrointestinal health and skin and tissue repair.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
